BACKGROUND: We previously demonstrated the efficacy of single-dose 6-monthly rituximab infusions in 25 adults with @entity479 -dependent minimal-change @entity1985 . Herein, we assessed the safety of rituximab treatment and its effect in ameliorating the adverse effects of @entity617 ( @entity16723 ) in a larger study sample. METHODS: We treated 54 adult @entity1 with four single-dose 6-monthly infusions of rituximab (375 mg/m(2) BSA per dose). We compared the adverse effects of @entity16723 ( @entity170 , @entity101 , and @entity6 ) between the first rituximab infusion (baseline) and the end of the 24-month observation period. In addition, we examined the adverse effects of rituximab during the same period. RESULTS: The @entity16723 dose was significantly lower at 24 months than at the baseline. The bone density was significantly higher at 24 months as compared to the baseline value (Z score -1.8 vs. -1.1; p < 0.05). Blood pressure at 24 months was significantly lower than that at the baseline (120.9/74.4 vs. 111.8/70.3 mm Hg; p < 0.05). Eight @entity1 with @entity6 showed improved glycemic control at 24 months as compared to that at the baseline. There were no severe adverse effects of rituximab. However, mild infusion reactions occurred in 31 @entity1 (57%). The frequency of the infusion reactions decreased significantly with every successive infusion. CONCLUSION: Rituximab treatment was effective and safe in @entity1 with @entity479 -dependent @entity1985 , allowed reduction of the @entity16723 dose, and ameliorated the adverse effects of @entity16723 . It may be preferentially used in @entity1 at a risk of the adverse effect of @entity16723 .

Amelioration of the adverse effects of XXXX by rituximab treatment in adults with @entity479 -dependent minimal-change @entity1985 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity16723 :: ('MESH:C036266', 'Chemical') :: ['PRED'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic syndrome'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone'] @entity479 :: ('D013256', 'Chemical') :: ['steroid']
@entity617 :: (MESH:D011239,Chemical) :: ['prednisolone']
